RxDoctor Payments DataLook up a doctor →

Ami Chitalia, MD

Hematology & Oncology · Washington, DCNPI 1083939102

Payments from drug & device makers

$1,754,586in general payments, 2019–2025

Across 253 payments — averaging $6935.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.1M
  • Novartis$367K
  • Genentech, Inc.$219K
  • Amgen$41K
  • Stemline Therapeutics Inc.$38K
  • Daiichi Sankyo Inc.$4K
  • plus $6K from 22 others

What the payments were for

  • Consulting fees$5,48047%
  • Speaking & faculty fees$4,00034%
  • Food & beverage$2,23719%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,754,586 in reported general payments places this provider in the 85th percentile of 69 hematology & oncology providers in District of Columbia.

See all hematology & oncology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$108,515
Medicare patients
294
Services billed
1,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Everolimus12$30,814
Exemestane92$20,388
Anastrozole246$3,795
Letrozole52$1,456
Dexamethasone15$368
Alendronate Sodium40$270
Olanzapine15$266
Gabapentin18$232
Lidocaine-PrilocaineLidocaine/Prilocaine12$143
Ondansetron Hcl19$106
Prochlorperazine Maleate15$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$86$26615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 69 hematology & oncology providers in District of Columbia.

Other hematology & oncology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →